期刊文献+

药物涂层球囊扩张时间与血管吸收药物量的离体实验研究

In Vitro Experiments of Inflation Time and Drug-transfer to Vessel for Drug-coated Balloon
下载PDF
导出
摘要 药物涂层球囊是使抑制增生的药物包裹在球囊外表面从而向病变部位转移药物的医疗器械,目前已经被临床广泛应用于治疗血管原位狭窄病变、支架内再狭窄等,并且取得了较好的效果。扩张时间在药物涂层球囊的临床使用中是一个非常重要的因素。该文定量分析药物涂层球囊在植入后扩张时间与血管吸收药物量的关系,为药物球囊的研发和临床使用提供指导。将药物球囊用于离体动物血管试验,测量不同的扩张时间下血管中的药物含量,分析血管吸收药物量与球囊扩张时间的关系。实验结果发现:球囊扩张时间在120s以内,血管对药物的吸收量随着扩张时间的增加而几乎呈线性增加。120s后,血管对药物的吸收量基本维持在15%左右,不再有明显增加。因此,血管对药物吸收量与药物涂层球囊扩张时间之间的关系是非线性的,不同的药物涂层球囊应该通过离体实验确定其在治疗血管狭窄时的最优扩张时间,从而可以使药物涂层球囊治疗效果达到最佳。 Drug-coated balloon(DCB)is a medical device that wraps drugs that inhibit proliferation on the outer surfece of the balloon to transfer drugs to the lesion site,and has been widely used in clinical treatment of vascular stenosis lesions,stent restenosis,etc.,and has achieved good results.Inflation time is a very important factor in the clinical use of drug-coated balloons.The article quantitatively analyzed the relationship between the inflation time of DCB after implantation and the drug-transfer to the vessel to provide guidance for the development and clinical application of DCB.DCBs were used for in vitro animal vascular test to measure the drug content in blood vessel under the different inflation times,and the relationship between the drug-transfer to the vessel and the inflation time was analyzed.The results indicated an almost linear increase of drug-transfer to the vessel with the increase of the inflation time but less than 120s.When the inflation time exceeded 120s,drug-transfer to the vessel was basically maintained at about 15%,no longer raised significantly.The following conclusions are drawn that the relationship between the drug-transfer to the vessel and inflation time is nonlinear,and the optimal inflation time of DCB in the treatment of vascular stenosis should be determined by in vitro testing in order to improve the treatment outcomes.
作者 张园园 张晨朝 卢楷 王盛章 刘继勇 ZHANG Yuanyuan;ZHANG Chenzhao;LU Kai;WANG Shengzhang;LIU Jiyong(Institute of Biomedical Engineering and Technology,Academy for Engineering&Technology,Fudan University,Shanghai 200433,China;Institute of Biomechanics,Department of Aeronautics and Astronautics,Fudan University,Shanghai 200433,China;Department of Pharmacy,Shanghai Cancer Center,Fudan University,Shanghai 200032,China;Yiwu Research Institute,Fudan University,Yiwu,Zhejiang 322000,China)
出处 《生物医学工程学进展》 CAS 2023年第1期58-64,共7页 Progress in Biomedical Engineering
基金 国家自然科学基金(32071310)。
关键词 药物涂层球囊 血管狭窄 扩张时间 药物吸收量 Drug-coated Balloon Vascular Stenosis Inflation Time Drug-transfer to the Vessel
  • 相关文献

参考文献7

二级参考文献37

  • 1Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle proliferation and migration in vitro and in vivo using local drug delivery[J] . Circulation, 1997, 96(2) :636-645.
  • 2Fanggiday JC, Stella PR, Guyomi SH, et al. Safety and efficacy of drug-eluting balloons in percutaneous treatment of bifurcation lesions= the DEBIUT (drug eluting balloon in bifurcation Utrecht) registry[J]. Catheter Cardiovasc Interv, 2008,71(5) :629-635.
  • 3Cremers B, Biedermann M, Mahnkopf D, et al. Comparison of two different paclitaxel-coated catheters in the porcine coronary restenosis model [ J] . Clin Res Cardiol, 2009, 98(5) :325-30.
  • 4Scheller B. Opportunities and limitations of drug-coated balloons in interventional therapies [J]. Herz,2011,36(3) :232-239.
  • 5Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymebased paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial [J]. JAMA, 2005, 294 (10) : 1215 -1223.
  • 6Vom Dahl J, Dietz U, Haager PK, et al. Rotational atherectomy does not reduce recurrent in-stent restenosis: results of the Angioplasty versus Rotational Atherectomy for Treatment of Diffuse In-Stent Restenosis Trial ( ARTIST ) [ J ]. Circulation,2002,105(5) :583-588.
  • 7Kastrati A, Mehilli J, von Beckerath N, et al. Sirolimus eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in- stent restenosis: a randomized controlled trial[J]. JAMA, 2005,293 (2) : 165-171.
  • 8Seheller B, Hehrlein C, Bockseh W, et al. Treatment of coronary in-stent restenosis with a paclitaxel coated balloon catheter[J]. N Engl J Med,2006,355(20) :2113-2124.
  • 9Scheller B, Hehrlein C, Bocksch W, et al. Two year follow- up after treatment of coronary in stent restenosis with a paclitaxel-coated balloon catheter[J]. Clin Res Cardiol,2008, 97(10) :773- 781.
  • 10HabaraS, MitsudoK, KadotaK, et al. Effectiveness of paclitaxel-elnting balloon catheter in patients with sirolimus- eluting stent restenosis[J]. JACC Cardiovasc Interv,2011,4 (2) : 149-154.

共引文献396

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部